Literature DB >> 22079446

Evaluation of the procoagulant activity of endogenous phospholipids in the platelet-free plasma of children with sickle cell disease using functional assays.

Denis C F Noubouossie1, Phu-Quoc Lê, Laurence Rozen, France Debaugnies, Alina Ferster, Anne Demulder.   

Abstract

BACKGROUND: The mechanisms of hypercoagulability in sickle cell disease (SCD) are poorly understood.
OBJECTIVE: We aimed to explore the procoagulant activity of endogenous phospholipids (ePL) in the platelet-free plasma of SCD children.
METHODS: A factor Xa clotting time (XACT), thrombin generation (TG) and a capture-based assay for the detection of procoagulant microparticles (PMP) were used. Forty three SCD children (35 SS, 6 SC and 2 Sβ+) were evaluated at steady-state and compared to 20 controls. Fourteen patients were also evaluated during vaso-occlusive crisis. TG was performed using 10 pM tissue factor without addition of exogenous phospholipids. A control condition was also performed using 10 pM tissue factor and 4 μM phospholipids. Percentages of the test/control conditions were calculated for the peak height (% peak), endogenous thrombin potential (% ETP) and velocity index (% VI).
RESULTS: XACT times were shorter, PMP levels, peak height and velocity index of thrombin generation were higher in SCD patients than controls. Lag time and ETP were not different between the two groups. % peak, % ETP and % VI were higher in patients than controls. Significant correlations were found between PMP levels and XACT, also between PMP levels and peak height, velocity index, ETP and their respective percentages to the control condition, but not with lag time. Double heterozygous patients showed intermediate values for XACT and TG parameters. No significant difference was observed when comparing patients at steady-state versus vaso-occlusive crisis.
CONCLUSION: High procoagulant activity of ePL was observed in the platelet-free plasma of SCD children, probably borne by procoagulant microparticles. This may contribute to a high hemostatic potential and predisposition to thrombotic complications in these patients.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22079446     DOI: 10.1016/j.thromres.2011.10.016

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Computational imaging analysis of fibrin matrices with the inclusion of erythrocytes from homozygous SS blood reveals agglomerated and amorphous structures.

Authors:  Rodney D Averett; David G Norton; Natalie K Fan; Manu O Platt
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

Review 2.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

3.  Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy.

Authors:  Raffaella Colombatti; Emiliano De Bon; Antonella Bertomoro; Alessandra Casonato; Elena Pontara; Elisabetta Omenetto; Graziella Saggiorato; Agostino Steffan; Tamara Damian; Giuseppe Cella; Simone Teso; Renzo Manara; Patrizia Rampazzo; Giorgio Meneghetti; Giuseppe Basso; Maria Teresa Sartori; Laura Sainati
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

4.  Circulating microparticles, protein C, free protein S and endothelial vascular markers in children with sickle cell anaemia.

Authors:  Andrea Piccin; Ciaran Murphy; Elva Eakins; Jan Kunde; Daisy Corvetta; Angela Di Pierro; Giovanni Negri; Mazzoleni Guido; Laura Sainati; Corrina Mc Mahon; Owen Patrick Smith; William Murphy
Journal:  J Extracell Vesicles       Date:  2015-11-23

5.  Is There Any Improvement of the Coagulation Imbalance in Sickle Cell Disease after Hematopoietic Stem Cell Transplantation?

Authors:  Laurence Rozen; Denis F Noubouossie; Laurence Dedeken; Phu Quoc Lê; Alina Ferster; Anne Demulder
Journal:  J Clin Med       Date:  2019-10-26       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.